|
 |
| INTERESTING IMAGE |
|
|
|
| Year : 2020 | Volume
: 35
| Issue : 3 | Page : 269-270 |
|
|
Tektrotyd scan showing a diffuse bone metastasis in patient with a neuroendocrine pancreatic tumor
Ali Sellem1, Yazid Mahjoub2, Wassim Elajmi1, Hatem Hammami1
1 Department of Nuclear Medicine, Military Hospital of Tunis, Tunis, Tunisia
2 Department of Nuclear Medicine, Hannibal International Clinic, Tunis, Tunisia
| Date of Submission | 31-Jan-2020 |
| Date of Acceptance | 26-Feb-2020 |
| Date of Web Publication | 01-Jul-2020 |
Correspondence Address:
Dr. Ali Sellem
Department of Nuclear Medicine, Military Hospital of Tunis, Tunis
Tunisia
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijnm.IJNM_17_20
 Abstract | | |
A 65-year-old woman presented with a neuroendocrine pancreatic head tumor and known liver and bone metastasis. We performed Tc-99m-tektrotyd scintigraphy on this patient, which showed more developed diffuse bone metastases, in addition to the known lesions.
Keywords: Bone marrow metastasis, neuroendocrine tumor, pancreatic tumor, somatostatinreceptor scintigraphy
How to cite this article:
Sellem A, Mahjoub Y, Elajmi W, Hammami H. Tektrotyd scan showing a diffuse bone metastasis in patient with a neuroendocrine pancreatic tumor. Indian J Nucl Med 2020;35:269-70 |
How to cite this URL:
Sellem A, Mahjoub Y, Elajmi W, Hammami H. Tektrotyd scan showing a diffuse bone metastasis in patient with a neuroendocrine pancreatic tumor. Indian J Nucl Med [serial online] 2020 [cited 2021 Jan 24];35:269-70. Available from: https://www.ijnm.in/text.asp?2020/35/3/269/288453 |
A 65-year-old woman with pancreatic neuroendocrine tumor (NET) who has hepatic and skeletal metastases discovered with contrast-enhanced computed tomography. The patient underwent two full-body scans acquired 15 min and 3 h after intravenous injection of 740 MBq (20 mCi) of 99m Tc-ethylenediammonium diacetate- tricine-hydrazinonicotinamide-Tyr0- octreotide (Tektrotyd) which showing an intense uptake in the area of the head pancreatic mass, in the liver metastasis [Figure 1] and in diffuse bone metastasis interesting the axial and peripheral skeleton [Figure 2]. | Figure 1: Single-photon emission computed tomography-computed tomography (TEKTROTYD) showing an intense uptake in the area of the head pancreatic mass (upper image) and a large metastasis in the liver segment VI (lower image)
Click here to view |
 | Figure 2: Whole-body scan (anterior and posterior) diffuse bone metastasis
Click here to view |
Pancreatic NETs are rare neoplasms that develop from the endocrine tissues of the pancreas. The reported incidence of 0.0003% to 0.001% of all cancers.[1],[2],[3] This incidence has been increasing throughout the world over the past two decades.[3],[4] About 32%–73% of cases are metastatic at the moment of diagnosis.[4],[5] The most common site of metastatic disease involvement for pancreatic NET is the liver.[6],[7],[8] Only 6%–13% of pancreatic NET patients will demonstrate skeletal metastasis.[9],[10] Diffuse bone metastases in the entire axial and appendicular skeleton, as the case of our patient, are rare.[9],[10],[11],[12],[13],[14] The European NET Society consensus guidelines recommend the use of both anatomic imaging, i.e. magnetic resonance imaging and functional whole-body imaging methods, including bone scintigraphy and somatostatin receptor scintigraphy (SRS), for the detection of bone metastases.[15] In the last few decades, the superior value of positron emission tomography/computed tomography (PET/CT) over SRS in the diagnosis of NENs, particularly after the introduction of 68Ga-DOTA-peptides that specifically bind to somatostatin receptors, has been widely demonstrated.[16] In our department, we do not have PET/CT that is why we use tektrotyd.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
| References | |  |
| 1. | Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-33.  |
| 2. | Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-72. |
| 3. | Hallet J, Law CH, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: A population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015;121:589-97. |
| 4. | Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335-42. |
| 5. | Zerbi A, Falconi M, Rindi G, Delle Fave G, Tomassetti P, Pasquali C, et al. Clinicopathological features of pancreatic endocrine tumors: A prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol 2010;105:1421-9. |
| 6. | Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin Oncol 2012;24:46-55. |
| 7. | Harring TR, Nguyen NT, Goss JA, O'Mahony CA. Treatment of liver metastases in patients with neuroendocrine tumors: A comprehensive review. Int J Hepatol 2011;2011:154541. |
| 8. | Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer 2016;139:2679-86. |
| 9. | Meijer WG, van der Veer E, Jager PL, van der Jagt EJ, Piers BA, Kema IP, et al. Bone metastases in carcinoid tumors: Clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med 2003;44:184-91. |
| 10. | Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, et al. Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect 2015;4:9-17. |
| 11. | Tomassetti P, Campana D, Piscitelli L, Casadei R, Santini D, Nori F, et al. Endocrine pancreatic tumors: Factors correlated with survival. Ann Oncol 2005;16:1806-10. |
| 12. | Cossetti RJ, Bezerra RO, Gumz B, Telles A, Costa FP. Whole body diffusion for metastatic disease assessment in neuroendocrine carcinomas: Comparison with OctreoScan ® in two cases. World J Surg Oncol 2012;10:82. |
| 13. | Basu S, Ranade R, Thapa P. Metastatic neuroendocrine tumor with extensive bone marrow involvement at diagnosis: Evaluation of response and hematological toxicity profile of PRRT with (177) Lu-DOTATATE. World J Nucl Med 2016;15:38-43. [ PUBMED] [Full text] |
| 14. | Adkins J, Lu Y. Diffuse bone metastases in pancreatic neuroendocrine tumor shown on octreoscan. Clin Nucl Med 2019;44:257-8. |
| 15. | Kos-Kudła B, O'Toole D, Falconi M, Gross D, Klöppel G, Sundin A, et al. ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 2010;91:341-50. |
| 16. | Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, et al. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: A prospective trial. J Nucl Med 2014;55:1598-604. |
[Figure 1], [Figure 2]
|
